“…As such, the role of CDNs in defense against pathogens as well as sensing of tumor cells makes them important for understanding, and potentially for treatment, of a number of autoimmune diseases [3], cancers [4], and viral diseases [5,6], as well as having potential as adjuvants in vaccines [7]. Noticeably, one of the most intensively studied ligand-protein binding equilibria is the interaction of the STING (or its mutants) with various CDNs, including chemically modified nucleobases, phosphodiester linkages, or sugar units [8,9]. Of the particular interest is the 2′,3′-cyclic diadenosine diphosphorothioate (2′,3′-c-di-AMPS) compound, known also as ADURO-S100, which was evaluated in Phase I clinical study.…”